This page shows the latest Waldenstrom's macroglobulinaemia news and features for those working in and with pharma, biotech and healthcare.
There was some positive news for Janssen, however, as Imbruvica received a positive recommendation to treat Waldenström's Macroglobulinaemia (WM) in adults who have had at least one prior therapy.
Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug. NICE has once again rejected Johnson &Johnson's Imbruvica (ibrutinib) for use on the NHS in England and Wales, ... Imbruvica is used to treat Waldenstrom's macroglobulinaemia
mantle cell lymphoma (MCL) and the treatment of Waldenström's macroglobulinaemia. ... AbbVie and J&J's drug also achieved partial or complete responses in 82% of patients, compared to 35% of the chemotherapy group.
Acalabrutinib is a Bruton's tyrosine kinase (Btk) inhibitor in the same class as Janssen/Pharmacyclics/Abbvie's Imbruvica (ibrutinib) drug for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia, which ... This week it agreed a
as a treatment for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia. . ... Analysts have speculated that AZ's interest in Acerta could draw other possible suitors out of the shadows.
of Waldenström's macroglobulinaemia. ... The drug still has a long way to go however to meet its $10bn-plus peak sales target - and also justify AbbVie's $21bn purchase of Pharmacyclics earlier this year - and
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....